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Precision oncology implies customiz-ing treatment to the unique molecu-
lar and biologic characteristics of each
individual and their cancer. Its imple-
mentation is being facilitated by remark-
able technological advances in genomic
sequencing, as well as the increasing
availability of targeted and immunother-
apeutic drugs. Yet, next generation
sequencing may be a disruptive technol-
ogy in that its results suggest that classic
paradigms for clinical research and prac-
tice are a poor fit with the complex reality
encountered in metastatic malignancies.
Indeed, it is evident that advanced
tumors have heterogeneous molecular
landscapes that mostly differ between
patients. Traditional modes of clinical
research/practice are drug centered, with
a strategy of finding commonalities
between patients so that they can be
grouped together and treated similarly.
However, if each patient with metastatic
cancer has a unique molecular portfolio,
a new patient-centered, N-of-one
approach that utilizes individually tai-
lored treatment is needed.
Precision oncology (personalized can-
cer therapy) entails tailoring treatment to
the unique molecular/biologic makeup of
each tumor. The basis for its implemen-
tation is decades of preclinical work
that identified specific molecular/biologic
aberrations that promote tumor growth
and/or evasion of host immune-surveil-
lance, and the development of targeted
treatments to prosecute these anomalies.
Technological tools that enable interro-
gation of genomic profiles have advanced
at a startling pace, with the first human
genome sequenced just over a decade ago
(costing approximately 3 billion dollars)
and taking years to accomplish, while
today full genomic next generation
sequencing (NGS) can be completed in
days for less than 5 thousand dollars.
Reclassification of Cancer
The reality unveiled by NGS fits
poorly with traditional oncology trials and
practice. Indeed, NGS represents a disrup-
tive technology whose findings dictate the
necessity of new approaches, including a
need for the reclassification of cancer.
Cancers are currently categorized accord-
ing to anatomical site of origin (e.g.,
breast, lung or colon cancer), yet oncolo-
gists have long recognized that tumors
originating in a particular organ respond
differently to the same agents and, further-
more, that drugs may be effective in can-
cers originating from different organs.
NGS provides a possible explanation,
since most molecular aberrations do not
segregate by organ of origin, and tumors
from different organs may have similar
mutations.2
Malignant Snowflakes
NGS has revealed a complicated pic-
ture—i.e., patients with metastatic cancers
have unique genomic landscapes; their
tumors may be “malignant snowflakes” in
that no 2 are identical.1 For instance, in 57
patients with metastatic breast cancer, we
observed 216 somatic aberrations (131
being distinct) in 70 different genes,
(NGS, 182 or 236 gene panel; median
D 4 aberrations/patient).1 As technologies
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improve to full genomic sequencing of
tumor and germ-line, additionally enabling
assessment of host variations influencing
drug metabolism/toxicity, it seems inevita-
ble that tumors will be defined by their
unique molecular signatures.
Innovative Approaches to Clinical
Research/Treatment
The reality that most tumors are dis-
tinct and driven by specific molecular
aberrations demands novel approaches.
The following have been proposed: (i) use
traditional clinical trial paradigms that
group patients together, but base therapy
on the molecular drivers, rather than just
tumor histology; or (ii) replace traditional
paradigms, and treat patients with cus-
tomized, individualized combinations of
drugs.3
The first approach has already
emerged, with the advent of genomically-
driven trials, either within histologies
(e.g., BRAF inhibitors for BRAF-mutant
melanoma) or so-called “bucket” or
“basket” trials that are histology-agnostic
(a BRAF inhibitor for any BRAF-mutant
cancer). (In many ways, the latter strategy
is analogous to classic organ-specific trials
(e.g., a colon cancer trial) that could be
viewed as a molecularly-agnostic “bucket”
trial for a particular histology).
The strategy of molecularly driven tri-
als has yielded remarkable responses in
several malignancies.4,5 However, few
patients with advanced solid tumors
achieve complete remission and almost all
relapse, probably because of the presence/
emergence of additional aberrations that
mostly differ between patients. Computer
algorithms that identify convergence path-
ways for multiple aberrations may enable
the continued grouping of individuals
with distinct molecular portfolios together
for the sake of treatment.6 However, even
if there is some convergence of genomic
paths, additional technologies such as
transcriptomics and proteomics, as well as
probing host polymorphisms, are likely to
reveal yet more complexity/individuality.
Distilling these myriad anomalies down to
a few signals that can be prosecuted with a
limited number of drugs appears unlikely.
For instance, the optimal drug (e.g., small
molecule inhibitor versus antibody) may
vary with the host proclivity to toxicity as
well as the specific part of the pathway
rendered abnormal, which in turn may
depend on the precise mutation.
The Conundrum of Combination
Therapy
Complicating the situation further is
the fact that most advanced neoplasms
harbor multiple molecular aberrations.
The strategy of grouping patients for
mono-therapy has been feasible, though
complicated. The need for combina-
tions of drugs to optimize response/cir-
cumvent resistance is however clear, as
few patients with advanced disease
achieve long-term survival with mono-
therapy. Yet, even tumors that have an
aberration in common often differ in
the rest of their molecular fingerprint.1
This fact makes grouping patients for
combination therapy a herculean task.
Indeed, the very definition of
“personalized” treatment is not consis-
tent with canonical trial and practice
paradigms, where patients are treated in
the same way based on some biologic
commonality. Rather, the data indicate
that, even if patients have an aberration
in common, the rest of their molecular
backdrop is distinct,1-3 and hence cus-
tomized individualized therapy—the N-
of-one approach—is required for opti-
mal results.
Individualized Treatment Outside
of the Cancer Field
There are several challenges that pres-
ent themselves when a strategy of individ-
ualized combination therapy is broached.
The most pronounced are related to con-
cerns about the safety of combinations of
anti-cancer drugs, when such combina-
tions have not undergone formal early-
phase testing. In this context, it is impor-
tant to examine the lessons learned from
the practice of medicine outside the cancer
field.
The typical patient with cancer is
already receiving 5 to 10 drugs for their
co-morbidities, which frequently
include heart disease, diabetes, depres-
sion, etc. The appropriate drugs are
routinely prescribed (without phase I
safety testing of the combinations)
based on patients’ “individual” co-mor-
bidities and well-known algorithms
regarding metabolism/organ function
that dictate safety. Why is cancer an
exception? The historic prohibition
against combining anti-cancer drugs
without formal phase I testing is likely
a legacy of the cytotoxic era. Cytotoxics
have considerable side effects resulting
in the legitimate concern that de novo
combinations would result in dangerous
toxicities. Targeted agents, however,
often have fewer side effects. Further-
more, there is a wealth of information
that has been gleaned from years of
practice in non-cancer fields on the rou-
tine, safe use of combinations tailored
to an individual’s condition, and this
information could be applied to anti-
cancer drugs. Algorithms/simulations
that incorporate multiple factors (e.g.,
toxicity, metabolism, targets, drug class,
need for initial dose reductions) could
be deployed to permit de novo combina-
tions of cancer drugs similar to what is
routinely done for patients with multi-
ple non-cancer illnesses
In summary, the following major
points emerge from discoveries in clinical
cancer genomics.
1. Cancer should to be reclassified based
on its molecular/biologic characteris-
tics, rather than just organ of origin.
2. Metastatic cancers appear to be
“malignant snowflakes,” each having
unique genomic portfolios.
3. If tumors are defined by their molecu-
lar makeup, advanced molecular tests
should be considered a standard diag-
nostic tool for patients with cancer.
4. Mono-therapy is unlikely to cure
patients with advanced/complex malig-
nancies. Customized combination
therapy will be required.
5. Customized combinations of drugs
are routinely prescribed outside the
cancer field, and tailored to the
patient’s co-morbidities. Algorithms
based in part on lessons learned
from years of such practice should
be developed in order to predict safe
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starting doses for de novo anticancer
combinations.
6. The definition of “personalized” treat-
ment is inconsistent with canonical
trial/practice paradigms, where
patients are grouped together based on
a biologic commonality. A patient-cen-
tered, N-of-one approach is needed to
optimize therapy.
7. Profound changes in many aspects of
current developmental therapeutics
practice in oncology will be required
to take maximal advantage of
the knowledge being generated by
molecular science. These changes will
require new consensus among the
patient, scientific, medical, industrial,
and regulatory stakeholders.
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